Cargando…

The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study

OBJECTIVE: This study aimed to evaluate the effectiveness of Ruxolitinib for acute/chronic graft-versus-host disease in children. METHODS: This study was a retrospective trial. We analyzed the clinical characteristics of children who responded poorly to previous treatment for graft-versus-host disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Wenli, Zhu, Guanghua, Qin, Maoquan, Li, Zhigang, Wang, Bin, Yang, Jun, Wang, Tianyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910527/ https://www.ncbi.nlm.nih.gov/pubmed/33654380 http://dx.doi.org/10.2147/DDDT.S287218

Ejemplares similares

Ruxolitinib for Therapy of Graft-versus-Host Disease
por: Neumann, Thomas, et al.
Publicado: (2019)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
por: Wang, Dong, et al.
Publicado: (2021)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
por: Sarmiento Maldonado, Mauricio, et al.
Publicado: (2017)

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
por: Lin, Yan, et al.
Publicado: (2023)

P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY
por: Van Der Wagen, L., et al.
Publicado: (2022)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
por: Watson, Allison P., et al.
Publicado: (2018)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
por: Hinterlang, Mélanie, et al.
Publicado: (2022)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
por: Muñiz, Ó., et al.
Publicado: (2022)

Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
por: Kaurinovic, Martina, et al.
Publicado: (2022)

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
por: Rodríguez-Gil, Alfonso, et al.
Publicado: (2022)

Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial
por: Isberner, Nora, et al.
Publicado: (2021)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

P1327: RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY
por: Chen, K., et al.
Publicado: (2022)

A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients
por: Sarmiento, Mauricio, et al.
Publicado: (2021)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
por: Wei, Cong, et al.
Publicado: (2021)

Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients
por: Gagliardi, Thomas A, et al.
Publicado: (2022)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
por: Ong, Jian Chun Matthew, et al.
Publicado: (2023)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies
por: Zhang, Meng-yun, et al.
Publicado: (2022)

Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre
por: Zhu, Guanghua, et al.
Publicado: (2021)

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
por: Bonig, Halvard, et al.
Publicado: (2023)

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Hengwei, et al.
Publicado: (2021)

Extracorporeal Photopheresis in Children with Chronic Graft-Versus-Host Disease
por: Kozlov, Andrey, et al.
Publicado: (2021)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
por: Locatelli, Franco, et al.
Publicado: (2023)

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
por: Dou, Liping, et al.
Publicado: (2022)

Acute graft versus host disease
por: Jacobsohn, David A, et al.
Publicado: (2007)

Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
por: Braun, Lukas M., et al.
Publicado: (2021)

A Rare Presentation of Acute on Chronic Graft Versus Host Disease
por: Khurana, Surbhi, et al.
Publicado: (2022)

Prognostic Implications of the NIH Consensus Criteria in Children with Chronic Graft-versus-Host Disease
por: Lee, Jae Wook, et al.
Publicado: (2011)

Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
por: Yang, Yingying, et al.
Publicado: (2019)

Progress in chronic graft-versus-host disease
por: Martin, Paul J
Publicado: (2011)

Oral Chronic Graft-Versus-Host Disease
por: Dean, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_no144i3it93h3bj704feq9r3kr